[Back To Content Page]

Current Gene Therapy

Volume 1, Number 1, May, 2001

Contents

Preface

Progress Toward Vector Design for Hematopoietic Stem Cell Gene Therapy
Robert G. Hawley  

Alphavirus Vectors for Gene Therapy Applications
Kenneth Lundstrom

Biomaterials for Gene Delivery: Atelocollagen-mediated Controlled Release of Molecular Medicines
Takahiro Ochiya, Shunji Nagahara, Akihiko Sano, Hiroshi Itoh, and Masaaki Terada

Genetic Vaccination for the Active Immunotherapy of Cancer
 Vincenzo Bronte

Cancer Gene Therapy by Adenovirus-Mediated Gene Transfer
Qiaohua Wu, Terence Moyana and Jim Xiang

The Use of Fas Ligand, TRAIL and Bax in Gene Therapy of Prostate Cancer
J. S. Norris, M. L. Hyer, C. Voelkel-Johnson, S. L. Lowe, S. Rubinchik and  J-Y. Dong

This is to acknowledge that the slide shown on the front cover of this journal was kindly supplied by Dr. Andres Hurtado-Lorenzo, Molecular Medicine and Gene Therapy Unit, School of Medicine, University of Manchester, U.K. The figure shows coronal section of the substantia nigra following the administration of the fluorescent retrograde tracer Fluorogold and recombinant adenovirus into the rat striatum. The adenovirus vector and Fluorogold are both transported retrogradely to the substantia nigra, where Fluorogold is detected by its fluorescence (green), and the adenovirus vector encoded transgene is detected by immunocytochemistry (seen in red). Nigral neurons whose axons took up Fluorogold and were infected by the adenovirus vector appear as red neurons (transgene-positive) that contain fluorogold (which is detected as yellow nuclei). This illustrates a technique utilised to study the effects of adenovirus encoded transgenes on the survival of nigral neurons to neurotoxic insults in experimental models of Parkinson's disease.